Alzheimer’s disease is a neurodegenerative disorder characterized by cognitive and behavioral problems. It is the most common form of dementia in the elderly with patients initially experiencing memory loss and confusion that gradually leads to behavior and personality changes, a decline in cognitive abilities and ultimately to severe loss of…
NYU Langone Medical Center, NYU School of Medicine scientists presented several new findings at the 2015 Alzheimer’s Association International Conference in Washington, D.C., July 18-23-2015. This is the largest conference focusing on Alzheimer’s disease, and brings together researchers and clinicians who focus on understanding the cause, treatment and prevention of…
Stanford University School of Medicine researchers have found microglia containing iron in the brains of people with Alzheimer’s disease (AD), a condition not verified in the brains of healthy people. The iron-containing cells appeared in the hippocampus, a critical area for memory that also degenerates in AD. The work appeared in the…
Last week, the Alzheimer’s Association gave much-deserved recognition to a pair of not-for-profit foundations for their dedication in supporting biomedical research on Alzheimer’s Disease. The Association selected the MetLife Foundation and GHR Foundation to receive the Jerome H. Stone Philanthropy Award for Alzheimer’s Research, which was awarded during this year’s Alzheimer’s Association International…
Researchers at New York University Langone Medical Center and the Nathan S. Kline Institute for Psychiatric Research (NKI) in New York recently discovered a potential therapeutic target for Alzheimer’s disease and provided more insight into the associated endosome dysfunction. The study was published in the journal…
Monoclonal antibodies developed by a team of scientists at the NYU Langone Medical Center’s Center for Cognitive Neurology may be a stepping-stone towards potential new treatments against neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease. The majority of neurodegenerative diseases, such as Alzheimer’s, Lewy Body and other dementias, Parkinson’s and prion diseases…
Accera, Inc. a clinical-stage biotechnology company based in Broomfield, Colorado, recently announced that 75% of patients have been enrolled in its NOURISH AD Phase 3 clinical trial assessing the efficacy of its investigational compound AC-1204 for the treatment of Alzheimer’s disease (AD). The company is expecting to enroll a total…
The Alzheimer’s Association and the Paul G. Allen Family Foundation recently announced the award of three grants to assess the role of the immune system in Alzheimer’s disease. The awards represent an investment of $500,000 to advance this understudied yet immense area of scientific knowledge, which could play a major role…
Brandywine Senior Living, a leading provider of quality care and services to seniors, has just partnered with the Alzheimer’s Association Delaware Valley Chapter to remind its residents living with this neurodegenerative disease of the joy of listening to music. Thanks to generous funding from the Association, residents will soon rediscover the…
Piramal Imaging recently announced that it will present nine studies on the effects of Neuraceq (florbetaben F18 injection) at the Alzheimer’s Association International Annual Conference (AAIC), July 18-23, 2015 at the Walter E. Washington Convention Center in Washington, D.C. Neuraceq is indicated for Positron Emission Tomography (PET) imaging of…
Get regular updates to your inbox.